Clinical Trials Logo

Primary Peritoneal Cancer clinical trials

View clinical trials related to Primary Peritoneal Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05456685 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

IMGN853 With Carboplatin in Second-line Treatment of FRĪ± Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Start date: September 28, 2022
Phase: Phase 2
Study type: Interventional

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

NCT ID: NCT05053750 Active, not recruiting - Clinical trials for Primary Peritoneal Cancer

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: December 14, 2021
Phase: Early Phase 1
Study type: Interventional

This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.

NCT ID: NCT04227522 Active, not recruiting - Ovarian Cancer Clinical Trials

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

MAMOC
Start date: June 8, 2020
Phase: Phase 3
Study type: Interventional

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

NCT ID: NCT03393884 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

OVATION 2
Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.

NCT ID: NCT03245892 Active, not recruiting - Clinical trials for Primary Peritoneal Cancer

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Start date: August 4, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out what effects, good or bad, the addition of nivolumab or the combination of nivolumab plus ipilimumab to typical chemotherapy has on the treatment of advanced high-grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin. The typical chemotherapy treatment is Carboplatin and Paclitaxel.

NCT ID: NCT01883297 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: January 2015
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating lymphocytes (TILs), autologous dendritic cells (DCs), and OKT3 (anti-CD3 antibody), along with low-dose interleukin-2 (IL-2) therapy.

NCT ID: NCT01570582 Active, not recruiting - Ovarian Cancer Clinical Trials

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Start date: March 2010
Phase: Phase 2
Study type: Interventional

purpose Primary endpoint - To evaluate the 24 month disease free survival Second endpoints - To evaluate the 24 month overall survival To analyze the toxicity and the quality of life

NCT ID: NCT01220154 Active, not recruiting - Ovarian Cancer Clinical Trials

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Start date: October 2010
Phase: Phase 1
Study type: Interventional

Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with advanced ovarian carcinoma.

NCT ID: NCT00799110 Active, not recruiting - Ovarian Cancer Clinical Trials

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This research study is evaluating the effect (good and bad) of a dendritic cell/tumor fusion vaccine in combination with the laboratory made agents GM-CSF and imiquimod on the participants immune system. Another purpose of this study is to determine the type and severity of any side effects associated with this new study vaccine. We will also be evaluating what effect the vaccine has on the participants cancer. Dendritic cell vaccines have already been tested in clinical trials involving participants with many different types of cancer. Dendritic cells are powerful immune-stimulating cells that are normally found in small amounts in the body and are responsible for immune responses against "foreign" substances that enter the body.